## Edgar Filing: INTRABIOTICS PHARMACEUTICALS INC /DE - Form 8-K

## INTRABIOTICS PHARMACEUTICALS INC /DE

Form 8-K May 30, 2001

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549

FORM 8-K

CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): May 29, 2001

INTRABIOTICS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter)

DELAWARE

(State or other jurisdiction of incorporation)

0-29993 (Commission File No.)

94-3200380 (IRS Employer Identification No.)

2021 STIERLIN COURT
MOUNTAIN VIEW, CALIFORNIA 94043
(Address of principal executive offices and zip code)

Registrant's telephone number, including area code: (650) 526-6800

\_\_\_\_\_

ITEM 5. OTHER EVENTS

On May 29, 2001, IntraBiotics Pharmaceuticals, Inc. and Biosearch Italia S.p.A. announced an amendment to the License and Supply Agreement, dated May 8, 1998, for the development and commercialization of certain formulations of ramoplanin in North America for the treatment or prevention of human disease. The press release announcing the amendment is filed as Exhibit 99.1 hereto.

ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS

(c) EXHIBITS.

# Edgar Filing: INTRABIOTICS PHARMACEUTICALS INC /DE - Form 8-K

99.1 Press Release, dated May 29, 2001, entitled "IntraBiotics and Biosearch Italia S.p.A. Amend Collaboration on Ramoplanin."

1

### SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

INTRABIOTICS PHARMACEUTICALS, INC.

Dated: May 29, 2001 By: /s/ SANDRA WROBEL

-----

Sandra Wrobel Chief Financial Officer and Vice President, Business Operations

2

#### INDEX TO EXHIBITS

99.1 Press Release, dated May 29, 2001, entitled "IntraBiotics and Biosearch Italia S.p.A. Amend Collaboration on Ramoplanin."